Jeff Yass’s Dyne Therapeutics DYN Stock Holding History

Jeff Yass’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	62,600 -49,300	-44%	-$917K	﹤0.01%	7343
2026 Q1	$2.03M	Sell	111,900 -83,100	-43%	-$1.43M	﹤0.01%	6149
2025 Q4	$3.81M	Buy	195,000 +105,700	+118%	+$2M	﹤0.01%	4483
2025 Q3	$1.13M	Buy	89,300 +72,600	+435%	+$828K	﹤0.01%	7052
2025 Q2	$159K	Sell	16,700 -20,900	-56%	-$230K	﹤0.01%	11456
2025 Q1	$393K	Sell	37,600 -25,300	-40%	-$362K	﹤0.01%	9433
2024 Q4	$1.48M	Buy	62,900 +16,000	+34%	+$473K	﹤0.01%	5982
2024 Q3	$1.68M	Buy	46,900 +27,900	+147%	+$1.11M	﹤0.01%	5635
2024 Q2	$671K	Sell	19,000 -86,700	-82%	-$2.52M	﹤0.01%	7540
2024 Q1	$3M	Buy	105,700 +68,200	+182%	+$1.54M	﹤0.01%	4514
2023 Q4	$499K	Buy	+37,500	New	+$366K	﹤0.01%	8673
2023 Q3	–	Sell	-12,000	Closed	-$135K	–	12208
2023 Q2	$135K	Buy	+12,000	New	+$142K	﹤0.01%	10675

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jeff Yass's DYN Position: Q2 2026 in Review

Jeff Yass reduced its Dyne Therapeutics (DYN) stake by 57% in Q2 2026, selling an estimated $1.15M and leaving 47,127 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #8087.

Jeff Yass first reported a position in DYN in Q1 2021 and has held it in 17 quarters since. The position peaked at $12.5M in Q1 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Jeff Yass held 47,127 shares of Dyne Therapeutics worth $1.05M as of Q2 2026.
Jeff Yass sold 61,597 Dyne Therapeutics shares in Q2 2026, an estimated $1.15M.
Dyne Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8087 holding.
Jeff Yass first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 17 quarters since.
Jeff Yass's Dyne Therapeutics position peaked at $12.5M in Q1 2024.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.